Predictors of cardio-kidney complications and treatment failure in patients with chronic kidney disease and type 2 diabetes treated with SGLT2 inhibitors.
Chronic kidney disease
Outcomes
Predictors
Treatment failure
Type 2 diabetes
Journal
BMC medicine
ISSN: 1741-7015
Titre abrégé: BMC Med
Pays: England
ID NLM: 101190723
Informations de publication
Date de publication:
10 01 2022
10 01 2022
Historique:
received:
12
08
2021
accepted:
17
11
2021
entrez:
10
1
2022
pubmed:
11
1
2022
medline:
27
1
2022
Statut:
epublish
Résumé
Clinical practice guidelines recommend sodium-glucose co-transporter 2 inhibitors (SGLT2is) to mitigate adverse kidney and cardiovascular outcomes in patients with type 2 diabetes (T2D), including patients with comorbid chronic kidney disease (CKD), also referred to as diabetic kidney disease (DKD), who are at even higher risk. In this study, we sought to identify predictors of cardio-kidney events, cardio-kidney complications, and treatment failure (i.e., addition/initiation of a new T2D class, insulin, or discontinuation of SGLT2is) after new initiation of SGLT2is in patients with CKD and T2D (DKD). In this retrospective cohort study, we identified adult patients with DKD who initiated SGLT2is between April 1, 2012, and June 30, 2019, in Optum claims data. Outcome rates per 1000 person-years (PY) are reported with 95% confidence intervals (CIs). Cox proportional hazards regression identified patient characteristics associated with each outcome. The study population consisted of 6389 initiators of SGLT2is. The rate of CV hospitalization was 26.0 (95% CI 21.6, 30.4) per 1000 PY. Baseline characteristics associated with higher risk of CV hospitalization included age, atrial fibrillation, peripheral vascular disease (PVD), and cancer. The rate of kidney hospitalization was 12.0 (95% CI 9.0, 15.0) per 1000 PY. The risk increased significantly with baseline evidence of heart failure, hyperkalemia, respiratory failure, depression, and use of loop diuretics. In total, 55.0% of all SGLT2i initiators discontinued treatment during the follow-up period. The rate of treatment failure was 510.5 (95% CI 492.9, 528.1) per 1000 PY. Analysis of key time-dependent SGLT2i-associated adverse events showed that experiencing diabetic ketoacidosis and volume depletion were associated with risk of treatment failure. Our study demonstrated high rates of residual cardio-kidney outcomes and treatment failure in patients with DKD treated with SGLT2is. Patients with high baseline CV risk and the presence of certain conditions, such as atrial fibrillation, PVD, and heart failure, were at higher risk for cardio-kidney events. Further research is needed to assess the potential relationship between adverse events and SGLT2i treatment failure.
Sections du résumé
BACKGROUND
Clinical practice guidelines recommend sodium-glucose co-transporter 2 inhibitors (SGLT2is) to mitigate adverse kidney and cardiovascular outcomes in patients with type 2 diabetes (T2D), including patients with comorbid chronic kidney disease (CKD), also referred to as diabetic kidney disease (DKD), who are at even higher risk. In this study, we sought to identify predictors of cardio-kidney events, cardio-kidney complications, and treatment failure (i.e., addition/initiation of a new T2D class, insulin, or discontinuation of SGLT2is) after new initiation of SGLT2is in patients with CKD and T2D (DKD).
METHODS
In this retrospective cohort study, we identified adult patients with DKD who initiated SGLT2is between April 1, 2012, and June 30, 2019, in Optum claims data. Outcome rates per 1000 person-years (PY) are reported with 95% confidence intervals (CIs). Cox proportional hazards regression identified patient characteristics associated with each outcome.
RESULTS
The study population consisted of 6389 initiators of SGLT2is. The rate of CV hospitalization was 26.0 (95% CI 21.6, 30.4) per 1000 PY. Baseline characteristics associated with higher risk of CV hospitalization included age, atrial fibrillation, peripheral vascular disease (PVD), and cancer. The rate of kidney hospitalization was 12.0 (95% CI 9.0, 15.0) per 1000 PY. The risk increased significantly with baseline evidence of heart failure, hyperkalemia, respiratory failure, depression, and use of loop diuretics. In total, 55.0% of all SGLT2i initiators discontinued treatment during the follow-up period. The rate of treatment failure was 510.5 (95% CI 492.9, 528.1) per 1000 PY. Analysis of key time-dependent SGLT2i-associated adverse events showed that experiencing diabetic ketoacidosis and volume depletion were associated with risk of treatment failure.
CONCLUSIONS
Our study demonstrated high rates of residual cardio-kidney outcomes and treatment failure in patients with DKD treated with SGLT2is. Patients with high baseline CV risk and the presence of certain conditions, such as atrial fibrillation, PVD, and heart failure, were at higher risk for cardio-kidney events. Further research is needed to assess the potential relationship between adverse events and SGLT2i treatment failure.
Identifiants
pubmed: 35000594
doi: 10.1186/s12916-021-02191-2
pii: 10.1186/s12916-021-02191-2
pmc: PMC8744296
doi:
Substances chimiques
Sodium-Glucose Transporter 2 Inhibitors
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2Informations de copyright
© 2021. The Author(s).
Références
Clin Pharmacol Ther. 2016 Mar;99(3):325-32
pubmed: 26690726
J Natl Med Assoc. 2004 Nov;96(11):1445-54
pubmed: 15586648
Curr Opin Endocrinol Diabetes Obes. 2017 Feb;24(1):73-79
pubmed: 27898586
Int J Mol Sci. 2021 May 28;22(11):
pubmed: 34071671
JAMA. 2016 Aug 9;316(6):602-10
pubmed: 27532915
Kidney Int. 2020 Oct;98(4S):S1-S115
pubmed: 32998798
J Endocrinol Invest. 2020 Mar;43(3):329-336
pubmed: 31515744
Clin J Am Soc Nephrol. 2012 Nov;7(11):1793-800
pubmed: 22904119
Pharmacoeconomics. 2016 Feb;34(2):169-79
pubmed: 26660349
Diabetes Obes Metab. 2020 Sep;22(9):1481-1495
pubmed: 32285611
Diabetes Care. 2004 May;27 Suppl 2:B10-21
pubmed: 15113777
BMJ Open Diabetes Res Care. 2020 May;8(1):
pubmed: 32448787
Am J Kidney Dis. 2020 Jan;75(1 Suppl 1):A6-A7
pubmed: 31704083
Diabetes Care. 2018 Jan;41(1):69-78
pubmed: 29109299
J Diabetes. 2020 Apr;12(4):279-293
pubmed: 31688975
Int J Mol Sci. 2021 May 01;22(9):
pubmed: 34062938
Int J Mol Sci. 2021 May 21;22(11):
pubmed: 34063872
Clin J Am Soc Nephrol. 2017 Dec 7;12(12):2032-2045
pubmed: 28522654
Medicina (Kaunas). 2021 Aug 25;57(9):
pubmed: 34577791
N Engl J Med. 2019 Jun 13;380(24):2295-2306
pubmed: 30990260
J Manag Care Spec Pharm. 2015 Dec;21(12):1162-70
pubmed: 26679965
Int J Clin Pract. 2015 Aug;69(8):871-82
pubmed: 26011029
Diabetes Obes Metab. 2020 Apr;22 Suppl 1:3-15
pubmed: 32267079
Rev Assoc Med Bras (1992). 2020 Jan 13;66Suppl 1(Suppl 1):s31-s36
pubmed: 31939533
Front Cardiovasc Med. 2020 May 13;7:88
pubmed: 32478100
Diabetes Metab Res Rev. 2019 Oct;35(7):e3171
pubmed: 30997935
Diabetes Obes Metab. 2019 May;21(5):1237-1250
pubmed: 30697905
Clin J Am Soc Nephrol. 2017 Aug 7;12(8):1366-1373
pubmed: 28280116
Biom J. 2018 May;60(3):431-449
pubmed: 29292533